Bosh sahifaNTLA • NASDAQ
Intellia Therapeutics Inc
10,20 $
13-yan, 0:30:59 (GMT-5) · USD · NASDAQ · Ogohlantirish
AksiyalarAQSH qimmatli qogʻoziBosh shtabi: AQSH
Yopilish kursi
12,02 $
Kunlik diapazon
9,93 $ - 11,43 $
Yillik diapazon
9,93 $ - 34,87 $
Bozor kapitalizatsiyasi
1,04 mlrd USD
Oʻrtacha hajm
2,36 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD)sen, 2024Y/Y qiyosi
Daromad
9,11 mln-24,02%
Joriy xarajat
30,50 mln3,73%
Sof foyda
-135,71 mln-11,04%
Sof foyda marjasi
-1,49 ming-46,15%
Har bir ulushga tushum
-1,342,90%
EBITDA
-142,16 mln-10,36%
Amaldagi soliq stavkasi
Jami aktivlari
Jami passivlari
(USD)sen, 2024Y/Y qiyosi
Naqd pul va qisqa investitsiyalar
658,11 mln-23,01%
Jami aktivlari
1,17 mlrd-5,63%
Jami passivlari
210,74 mln2,33%
Umumiy kapital
962,62 mln
Tarqatilgan aksiyalar
101,85 mln
Narxi/balansdagi bahosi
1,27
Aktivlardan daromad
-30,61%
Kapitaldan daromad
-33,80%
Naqd pulning sof oʻzgarishi
(USD)sen, 2024Y/Y qiyosi
Sof foyda
-135,71 mln-11,04%
Operatsiyalardan naqd pul
-84,84 mln16,32%
Sarmoyadan naqd pul
-7,71 mln-109,70%
Moliyadan naqd pul
82,19 mln330,28%
Naqd pulning sof oʻzgarishi
-10,35 mln-272,58%
Boʻsh pul
-35,80 mln44,08%
Haqida
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Tashkil etilgan
2014
Xodimlar soni
526
Yana
Bu sizni qiziqtirishi mumkin
Bu roʻyxat oxirgi qidiruvlar, kuzatilgan aksiyalar va boshqa faoliyatdan tuzilgan. Batafsil

Barcha axborotlar faqat maʼlumot sifatida “shundayligicha” taqdim etilgan, ulardan moliyaviy maslahat sifatida foydalanmang, ular savdo maqsadlari yoki investitsiya, soliq, yuridik, buxgalteriya yoki boshqa turdagi maslahat emas. Google investitsiya borasida maslahatchi emas, bu roʻyxatdagi kompaniyalar yoki ularning aksiyalari borasida hech qanday nuqtai nazar, tavsiya yoki fikr bildirmaydi. Har qanday savdoni boshlashdan oldin broker yoki moliyaviy vakil bilan maslahatlashib, narxlarni tekshiring. Batafsil
Aloqador qidiruvlar
Qidiruv
Qidiruv maydonini tozalash
Qidiruvni yopish
Google ilovalari
Asosiy menyu